|
1
|
Labianca R, Nordlinger B, Beretta GD,
Mosconi S, Mandalà M, Cervantes A and Arnold D: ESMO Guidelines
Working Group: Early colon cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24
Suppl 6:vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
World Cancer Report 2014. World Health
Organization. Chapter 1.1. 2014
|
|
3
|
Welch JP and Donaldson GA: The clinical
correlation of an autopsy study of recurrent colorectal cancer. Ann
Surg. 189:496–502. 1979.PubMed/NCBI
|
|
4
|
Borner MM: Neoadjuvant chemotherapy for
unresectable liver metastases of colorectal cancer-too good to be
true? Ann Oncol. 10:623–326. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pamies RJ and Crawford DR: Tumor markers.
An update. Med Clin North Am. 80:185–199. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perkins GL, Slater ED, Sanders GK and
Prichard JG: Serum tumor markers. Am Fam Physician. 68:1075–1082.
2003.PubMed/NCBI
|
|
7
|
Clinical practice guidelines for the use
of tumor markers in breast and colorectal cancer. Adopted on May
17, 1996 by the American Society of Clinical Oncology. J Clin
Oncol. 14:2843–2877. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fletcher RH: Carcinoembryonic antigen. Ann
Intern Med. 104:66–73. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gupta MK, Arciaga R, Bocci L, Tubbs R,
Bukowski R and Deodhar SD: Measurement of a
monoclonal-antibody-defined antigen (CA19-9) in the sera of
patients with malignant and nonmalignant diseases. Comparison with
carcinoembryonic antigen. Cancer. 56:277–283. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kirchhoff C, Habben I, Ivell R and Krull
N: A major human epididymis-specific cDNA encodes a protein with
sequence homology to extracellular proteinase inhibitors. Biol
Reprod. 45:350–357. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Drapkin R, von Horsten HH, Lin Y, Mok SC,
Crum CP, Welch WR and Hecht JL: Human epididymis protein 4 (HE4) is
a secreted glycoprotein that is overexpressed by serous and
endometrioid ovarian carcinomas. Cancer Res. 65:2162–2169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Galgano MT, Hampton GM and Frierson HF Jr:
Comprehensive analysis of HE4 expression in normal and malignant
human tissues. Mod Pathol. 19:847–853. 2006.PubMed/NCBI
|
|
13
|
Kirchhoff C: Molecular characterization of
epididymal proteins. Rev Reprod. 3:86–95. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clauss A, Lilja H and Lundwall A: A locus
on human chromosome 20 contains several genes expressing protease
inhibitor domains with homology to whey acidic protein. Biochem J.
368:233–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thompson RC and Ohlsson K: Isolation,
properties, and complete amino acid sequence of human secretory
leukocyte protease inhibitor, a potent inhibitor of leukocyte
elastase. Proc Natl Acad Sci USA. 83:6692–6696. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Plebani M: HE4 Study Group: HE4 in
gynecological cancers: Report of a European investigators and
experts meeting. Clin Chem Lab Med. 50:2127–2136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brennan DJ, Hackethal A, Metcalf AM,
Coward J, Ferguson K, Oehler MK, Quinn MA, Janda M, Leung Y,
Freemantle M, et al: Serum HE4 as a prognostic marker in
endometrial cancer-a population based study. Gynecol Oncol.
132:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Z, Luo Z, Zhao B, Zhang W, Zhang J,
Li Z and Li L: Diagnosis and preoperative predictive value of serum
HE4 concentrations for optimal debulking in epithelial ovarian
cancer. Oncol Lett. 6:28–34. 2013.PubMed/NCBI
|
|
19
|
Simmons AR, Baggerly K and Bast RC Jr: The
emerging role of HE4 in the evaluation of epithelial ovarian and
endometrial carcinomas. Oncology (Williston Park). 27:548–556.
2013.PubMed/NCBI
|
|
20
|
Yu S, Yang HJ, Xie SQ and Bao YX:
Diagnostic value of HE4 for ovarian cancer: A meta-analysis. Clin
Chem Lab Med. 50:1439–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin J, Qin J and Sangvatanakul V: Human
epididymis protein 4 for differential diagnosis between benign
gynecologic disease and ovarian cancer: A systematic review and
meta-analysis. Eur J Obstet Gynecol Reprod Biol. 167:81–85. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hellstrom I, Raycraft J, Hayden-Ledbetter
M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N and
Hellström KE: The HE4 (WFDC2) protein is a biomarker for ovarian
carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
|
|
23
|
Zhen S, Bian LH, Chang LL and Gao X:
Comparison of serum human epididymis protein 4 and carbohydrate
antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin
Oncol. 2:559–566. 2014.PubMed/NCBI
|
|
24
|
Iwahori K, Suzuki H, Kishi Y, Fujii Y,
Uehara R, Okamoto N, Kobayashi M, Hirashima T, Kawase I and Naka T:
Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Tumour Biol. 33:1141–1149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagy B Jr, Bhattoa HP, Steiber Z, Csobán
M, Szilasi M, Méhes G, Müller M, Lázár J, Kappelmayer J and
Antal-Szalmás P: Serum human epididymis protein 4 (HE4) as a tumor
marker in men with lung cancer. Clin Chem Lab Med. 52:1639–1648.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo YD, Wang JH, Lu H, Li XN, Song WW and
Zhang XD: The human epididymis protein 4 acts as a prognostic
factor and promotes progression of gastric cancer. Tumour Biol.
36:2457–2464. 2015. View Article : Google Scholar : PubMed/NCBI
|
